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Healthy ageinga b s t r a c t
Background: Expanding vaccination programs for the older population might be important as older adults
are becoming a larger proportion of the general population. The aim of this study is to determine the rel-
ative importance of vaccine and disease specific characteristics and acceptance for Dutch older adults,
including pneumococcal disease, herpes zoster, pertussis vaccination, and influenza vaccination.
Methods: A discrete choice experiment was conducted to generate choice data that was analyzed using a
mixed multinomial logit statistical model.
Results: Important factors that were associated with vaccination acceptance in older adults are high mor-
tality risk of the infectious disease, high susceptibility of getting the infectious disease, and high vaccine
effectiveness. Age, influenza vaccination in 2013 and self-perceived health score were identified as per-
sonal factors that affect vaccine preference. Potential vaccination rates of older adults were estimated at
68.1% for pneumococcal vaccination, 58.1% for herpes zoster vaccination, 53.9% for pertussis vaccination
and 54.3% for influenza vaccination. For persons aged 50–65, potential vaccination rates were estimated
at 58.1% for pneumococcal vaccination, 49.5% for herpes zoster vaccination, 43.9% for pertussis vaccina-
tion and 42.2% for influenza vaccination. For persons aged 65 and older, these were respectively 76.2%,
67.5%, 57.5% and 65.5%.
Discussion: Our results suggest that older adults are most likely to accept pneumococcal vaccination of
the four vaccines. Information provision accompanied with the implementation of a new vaccine has
to be tailored for the individual and the vaccine it concerns. Special attention is needed to ensure high
uptake among persons aged 50–65 years.
 2017 Elsevier Ltd. All rights reserved.1. Introduction
Routine childhood vaccination has shown to be one of the most
successful strategies to reduce the burden of infectious diseases
[1]. For the older adult population (aged 50 years and older), in
many countries currently only influenza vaccination is common
to prevent disease burden. In the Netherlands, influenza vaccina-
tion is offered to all persons aged 60 years and older. Nevertheless,
other vaccinations such as pneumococcal, herpes zoster and per-
tussis vaccinations are available and licensed [2]. Expanding vacci-
nation programs for the older population might be important as
older adults are becoming a larger proportion of the general popu-
lation. Where transmission of infectious diseases in care facilitiesfor the aged are already high, community dwelling older adults
will be more socially engaged, which increases the transmission
chance of infectious diseases towards this population [3,4]. As a
result, prevalences of infectious diseases could rise increasing
healthcare demands. Vaccination may yield both individual health
benefits (not becoming sick) as well as societal benefits (i.e., lower
healthcare demands and costs) as demonstrated by childhood vac-
cinations [1]. One of the most important factors for any vaccination
program to be successful, is the acceptance of such a measure. Var-
ious factors such as vaccine and disease specific characteristics and
personal factors have been identified that play an important role in
the individual decision making process to accept vaccination of
persons aged 50 years and older [5,6]. Yet, the relative importance
of these identified factors is largely unknown. Obbtaining such
information is important to optimize the implementation of vacci-
nes and education programs for health professionals.
Therefore, the aim of this study is to reveal the relative impor-
tance of vaccine- and- disease specific characteristics that play a
2824 R. Eilers et al. / Vaccine 35 (2017) 2823–2830role in the individual decision-making process and final acceptance
of four (candidate) vaccines (pneumococcal disease, herpes zoster,
pertussis vaccination, and influenza vaccination) among Dutch
persons aged 50 years and older. For that purpose, we performed
a discrete choice analysis to identify vaccine preferences in this
population
2. Methods
2.1. Discrete choice experiment
The term discrete choice experiment (DCE) refers to an experi-
ment that is constructed to collect stated preference data (choices
made by individuals under experimental conditions) from survey
responses to hypothetical, but realistic scenario’s [7]. Using this
method in the field of healthcare assumes that healthcare inter-
ventions, services, or policies can be described by their character-
istics (or attributes). DCE scenarios are characterized by specific
attributes (characteristics) of which each attribute is varied by a
specified range of categories, called levels. Scenarios are con-
structed from a combination of these levels. One choice task is
comprised of at least two different scenarios. It is assumed that
within one choice task, individuals choose the scenario they prefer
most. Each respondent receives multiple choice tasks [8]. The data
from the DCE is used to estimate the relative importance of the
attributes and their associated levels by applying linked statistical
modelling [9].
2.2. Selection of attributes and levels
Based on a literature review [5] and a focus group study [10],
the following attributes were included in the DCE: clinical symp-
toms, susceptibility, mortality rate, vaccine effectiveness, side-
effects and number of vaccinations. Levels were formulated based
on information derived from the focus groups and the specific
available clinical disease and vaccine information of pneumococ-
cal, herpes zoster, influenza and pertussis. This resulted in realistic
scenarios suitable for the study population.Table 1
The attributes and associated levels for the 4 diseases included in the discrete choice exp
Attribute Levels
Clinical symptoms The vaccine protects against pertussis characterized by 1 to 3
tightness of the chest and sleep deprivation [1]
The vaccine protects against shingles, characterized by 2 week
could develop into chronic pain [2]
The vaccine protects against pneumonia, characterized by 2 we
and fever [3]
The vaccine protects against the flu, characterized by up to 1
shivers [4]
Susceptibility 1 out of 100 persons get the disease [1]
Half of the people get the disease [2]
Everyone gets the disease [3]
Mortality 1 out of 100 persons with this disease dies [1]
20 out of 100 persons with this disease die [2]
Vaccine
effectiveness
Half of the people are protected by the vaccine [1]
Everyone is protected by the vaccine [2]
Side effects The injection site is painful and swollen for 1 day [1]
Not feeling well for a few days which requires to stay home [
Number of given
vaccinations
The vaccine has to be given once [1]
The vaccine has to be given twice [2]
a Information on herpes zoster was obtained from [2,11], information on pneumococ
[2,11] and information on influenza was obtained from [13,14].Table 1 shows the assigned levels to the six attributes in the
choice experiment.
Unlabelled scenarios (not explicitly mentioning the type of vac-
cine or disease on top of each of the two scenarios) were chosen to
reduce possible insensitive responses (no trading between attri-
butes) as people may focus disproportionally much on the labels
[15].
An opt-out option (indicating no vaccination) was added as vac-
cination is not obligated in the Netherlands in real life. The attri-
butes in which risks were included were dichotomised as much
as possible. In addition, risks were presented in both text (as a risk
label) and pie charts to make the interpretation as easy as possible
[16,17] (Fig. 1).2.3. DCE design
The choice tasks were generated by running a D-efficient design
(Ngene Software version 1.1.1, http://www.choice-metrics.com).
Such a design takes into account prior knowledge concerning the
respondent’s preferences and limits the generation of dominant
scenarios (an obvious preferred scenario). Therefore, small (0.01)
positive and negative priors were included in building the design
to account for prior knowledge, these were the same for all level
across all attributes.
Based on this procedure, the final design consisted of 36 choice
tasks which were divided over six blocks of 6 choice tasks (by
NGene). The attribute levels varied across all choice tasks. The
number of choice tasks was set on six to reduce the cognitive bur-
den on the respondents. Each choice task was introduced with the
question: ‘Imagine that these two vaccines were offered to you for
vaccination; which vaccine do you prefer?’. The initial survey was
pilot tested to ensure correct wording and to test whether respon-
dents understood the provided information as well as the choice
tasks of the DCE. Think out loud testing (a respondent completes
the survey, reading it out loud, in the presence of the researcher)
with eight persons ranging in age from 52 to 82 was used as part
of the pilot test.eriment.
Associated diseasea
months of coughing, episodes with Pertussis
s of itching and painful skin rash that Herpes Zoster
eks of coughing, tightness of the chest Pneumococcal disease




Pertussis, herpes zoster, influenza
Pneumococcal disease
Pneumococcal disease, herpes zoster,
influenza
Pertussis
Pneumococcal disease, herpes zoster,
pertussis, influenza
2]
Pneumococcal disease, herpes zoster,
pertussis, influenza
cal disease was obtained from [2,12], information on pertussis was obtained from
Not feeling well for a few days which 
requires you to stay home
Choice 1
Disease: The vaccine protects 
against pertussis, 
characterized by 1 to 3
months of coughing 
together with with thightness 
of the chest and sleep deprivation
Everyone is protected 
by the vaccine 
The vaccine has to be given once
Everyone gets the
disease
1 out of 100 
people with this 
disease die
The injection site is painfull and 
swollen for one day 
Choice 2
Disease: The vaccine protects
against shingles, characterized 
by 2 weeks of itching and 
painful skin rash that could 
develop into chronic pain
The vaccine has to be given twice
Half of the people get
the disease
20 out of 100 people
with this disease 
die
Half of the people are
protected by the 
vaccine
Fig. 1. Example of two scenarios from which respondents had to choose the preferred one.
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After the choice tasks, demographics and other personal factors
were collected. These included standard aspects such as age, sex,
education and questions on the lifestyle and social context of the
participants. Current health was assessed with the EQ-VAS health
state scale indicator of the EQ-5D [18]. Health literacy scores were
gathered by using the Set Brief of Screening Questions [19]. This set
comprises of three questions assessing the problems understand-
ing health (care) related information, filling out medical forms
and finding health related information. Health literacy level was
calculated on the answers given to these three questions [20]. A
‘healthy living’ variable was also constructed combing non-
smoking with 1 time exercise in the week.2.5. Respondents
Six municipalities were asked to take a random sample of their
population based on four age categories: 50–60 years, 60–70 years,
70–80 years and 80 years and older. We choose to set the age limit
to 50 years because vaccinating at that age might have biological
advantages (i.e., before the onset of immunosenescence (the grad-
ual deterioration of the immune function). The municipalities wereselected based on the urbanisation level and their geographical
location. In total, 1800 potential respondents were selected. A
postal survey was sent during December 2014. After three weeks,
a reminder was sent to the non-responders. Persons returning
the survey received a gift voucher of 10 euro. Each survey was
accompanied with an invitation letter, giving information about
the study, explaining the purpose of the study and contact infor-
mation if there were any questions.2.6. Discrete choice analysis
Respondents were excluded if one or more of the choice tasks
were not filled in (i.e., more than 10% missing values). Nlogit (ver-
sion 5, http://www.limdep.com/) was used for choice modelling
and SAS version 9.3 (http://www.sas.com) for the preparation of
the data, including for example data cleaning, creating age groups
and health literacy scores.
Data were analyzed using a mixed multinomial logit statistical
model. This model takes into account possible preference hetero-
geneity and adjusts for the multilevel structure (one respondent
makes more than one choice) of the data. The aim of this analysis
was to estimate the relative importance of the attributes using the
following formula:
2826 R. Eilers et al. / Vaccine 35 (2017) 2823–2830Vim ¼ b1  clinical symptoms pertussis
þ b2  clinical symptoms herpes zoster
þ b3  clinical symptoms pneumoniaþ b4 mortality 20%
þ b5  susceptibility 50%þ b6  susceptibility 100%
þ b7  vaccine effectiveness 100%þ b8  side effects severe
þ b9  vaccinating twiceTable 2
The characteristics of the study population (n = 610).
Characteristic Statistics (%)

























Having a partner 78.3
Having a chronic disease 58.4
Asthma or COPD 10.2
Diabetes 8.9
Chronic heart disease 10.7
Rheumatism 17.7
High blood pressure 30.7
Osteoporosis 9.4






<1 time a day 23.8
1 time a day 25.1
>1 time a day 51.1
Flu vaccination 2013
Study population 59.8
Persons  60 years 72.7Voptout ¼ b0
The statistical model estimates the observed utility or ‘Vim’ (the
sum of all coefficients), that is the utility an individual (i) derives
from choosing an alternative (m) (or vaccine in this study) for each
choice task. The opt-out formula estimates the a priori preference
of respondents declining vaccination (i.e., choosing to opt-out)
over accepting vaccination.
The sign of the estimates of the attribute (levels) displays if this
attribute (level) has a positive or a negative influence on measur-
able utility. Based on model fit tests (AIC and Chi-square), the con-
stant, clinical symptoms, mortality, susceptibility and effectiveness
attributes were included as random parameters. The estimates of
these random parameters include a standard deviation (SD)
assuming normal distribution. By including random parameters,
the model accounts for any heterogeneity in the preference of
the respondents concerning those attributes. The presence of pref-
erence heterogeneity does not indicate subgroups within a popula-
tion per se (e.g., heterogeneity for the susceptibility attribute does
not automatically mean that older adults with poorer health
choose substantially different for all attributes).
Effects coding was used for the attribute levels, which allows
estimation of all level effects. [21]. This coding procedure codes
the reference category as 1 and the sum of the effect coded attri-
bute levels is always zero. Estimates of the reference category can
therefore be calculated as (b1 + b2 + bn)⁄  1.
Using the attribute level estimates, the vaccination uptake for
different vaccine candidates was estimated using: 1/(1 + expv)
[22].
Because V includes random parameters, the standard deviation
of these parameters should be taken into account [8]. This was
done by taking 10,000 draws from a normal distribution for each
random parameter (i.e., the mean and SD values were retrieved
from the mixed logit model). For every draw of the random param-
eter, the observed utility ‘‘V” as well as the potential coverage rate
was calculated. The average of the 10,000 calculated potential vac-
cination uptake was reported. A p-value of 0.10 for the levels was
considered statistically significant in all analyses.
Separate models were run for persons aged 50–65 years and
persons aged 65 years and older in order to compare estimated
uptake for influenza with the actual uptake among individuals
aged 65 years and older. For future programs expected uptake
among 50–65 year olds were of interest. Impact on choice behavior
of the different personal factors was assessed by adding each vari-
able as a covariate to the mixed multinomial logit model. Based on
literature the variables that were tested were: ‘sex’, ‘education’, ‘in-
fluenza vaccination received in 2013’ and ‘health score’. Interaction
terms were constructed between the attributes and significant per-
sonal factors to assess the specific influence of these factors on the
attributes.a Low education: no education or elementary education or
prevocational training mediate education: intermediate general
secondary education or technical and vocational training or
senior general secondary education or pre-university education
high education: higher professional education or academic
education.
b Including voluntary work.
c Defined as non-smoking and at minimum exercise once a
week.3. Results
3.1. Study population
In total, 735 surveys were returned (response rate = 41%). Over-
all, 610 respondents were included in the analysis due to excludingpersons with missing data in one (or more) of the DC tasks. Persons
aged 60–70 years more often returned the survey and relatively
less surveys were received from people aged 80 and older (33%
compared to 16% of the respondents). More men than women com-
pleted the survey (51.8% vs. 48.2%). Our study population consists
of fewer people with the non-Dutch nationality in comparison to
the general older adults population (1.3% vs. 3%) [23] and more
higher educated older adults (32% vs. 24%) (Statistics Netherlands,
2016]. In addition, self-reported influenza vaccination rate in this
study (72.7%) is higher than the actual vaccination rate that year
(67.2%) for persons aged 60 years and older [24] (Table 2).
R. Eilers et al. / Vaccine 35 (2017) 2823–2830 28273.2. Vaccine preferences
In total, 11% of the respondents always choose not to vaccinate
(opt-out). Within the total population, respondents preferred a
vaccine that protects against an infectious disease with a highest
mortality rate, highest susceptibility rate, that is most effective
and for which only one vaccination is required. People preferred
to be vaccinated against the clinical symptoms of pneumococcal
disease over those of influenza and preferred vaccination against
the clinical symptoms of influenza over those of pertussis and her-
pes zoster. Mild side-effects did not affect vaccine decision-making
(Table 3).
Both persons aged 50–65 years and persons aged 65 years and
older preferred a vaccine against a disease with 20% mortality over
1% mortality, 100% susceptibility rate over 1% and a vaccine with
100% effectiveness over 50% effectiveness. While the number of
required vaccinations did affect vaccination preferences among
persons aged 65 and older, this attribute was insignificant among
the persons aged 50–65. Persons aged 50–65 years preferred vacci-
nation against the clinical syndrome of pertussis over influenza
while persons aged 65 years and older significantly preferred influ-
enza vaccination over pertussis vaccination. Both groups preferred
vaccination against the clinical syndrome of pneumococcal disease
over influenza (Table 3).Table 3
Estimated coefficients for the complete study population and sub age populations (n = 61
Total study population
Attribute levels Coefficient Std. erro
Constantb Mean 1.24*** 0.23
SD 4.21*** 0.28
Clinical syndromes
Pertussis Mean 0.34*** 0.09
SD 1.21*** 0.13
Herpes Zoster Mean 0.15* 0.09
SD 1.19*** 0.13
Pneumococcal disease Mean 0.54*** 0.08
SD 0.64*** 0.14
Influenza (ref) Mean 0.04 0.11
SD 1.81 1.72
Mortality
1% mortality (ref) Mean 0.52*** 0.06
SD 0.91*** 0.08
20% mortality Mean 0.52*** 0.06
SD 0.91*** 0.08
Susceptibility
1% susceptibility (ref) Mean 0.72*** 0.08
SD 0.78 0.74
50% susceptibility Mean 0.07 0.06
SD 0.34* 0.13
100% susceptibility Mean 0.65*** 0.07
SD 0.70*** 0.11
Vaccine effectiveness
50% vaccine effectiveness (ref) Mean 0.33*** 0.04
SD 0.31*** 0.08
100% vaccine effectiveness Mean 0.33*** 0.04
SD 0.31*** 0.08
Vaccine side-effects
Mild side-effects (ref) Mean 0.03 0.04
Severe side-effects Mean 0.03 0.04
Nr. of vaccinations
Vaccinating once (ref) Mean 0.07** 0.04
Vaccinating twice Mean 0.07** 0.04
a Reference levels: Coefficients were calculated by (b1 + b2 + bn)*  1 for each attribute
b The coefficient of the constant shows the preference of declining vaccination (choos
* P < 0.10.
** P < 0.05.
*** P < 0.01.3.3. Vaccine preference actors
The variables ‘Influenza vaccination received in 2013’ and
‘Health score’ were identified as personal factors that affect vaccine
preference. Persons who received the flu vaccination in 2013
reported a higher preference for vaccination against the clinical
syndromes of influenza compared to pertussis and herpes zoster
compared to persons that did not receive the flu vaccination in
2013.
Persons with a higher self-rated health score attach more
importance to a vaccine that protects against an infectious disease
with a 20% mortality rate, a vaccine with 100% effectiveness and a
vaccine that has to be given twice in comparison to persons with a
lower self-reported health score (Table 4).
3.4. Estimated vaccine acceptance
The estimated potential vaccination rates for the different vac-
cines were calculated for the 50 years and older study population
as well as for those aged 50–65 years and those aged 65 years
and older (Table 5). The estimated vaccination rate for pneumococ-
cal disease is highest in overall and for the two age groups (68.1%,
58.1%, and 76.2% respectively). For all vaccines, the estimated
uptake was lower for persons aged 50–65 compared to persons0).a
Population aged 50–65 Population aged 65 and over
r Coefficient Std. error Coefficient Std. error
0,24 0.37 1.83*** 0.28
5.04*** 0.50 3.34*** 0.30
0,29* 0.16 0.65*** 0.12
1.42*** 0.21 1.02*** 0.16
0,32** 0.16 0.06 0.11
1.58*** 0.23 1.07*** 0.16
0.55*** 0.13 0.52*** 0.10
0.80*** 0.21 0.65*** 0.18
0.52** 0.20 0.18** 0.07
2.27 2.20 1.61* 1.51
0.75*** 0.11 0.38*** 0.09
0.90*** 0.13 0.89*** 0.11
0.75*** 0.11 0.38*** 0.07
0.90*** 0.13 0.89*** 0.11
1.05*** 0.15 0.53*** 0.05
0.92* 0.73 0.92** 0.67
0.12 0.12 0.06 0.08
0.60*** 0.20 0.36** 0.15
0.93*** 0.13 0.48*** 0.09
0.69*** 0.18 0.65*** 0.14
0.40*** 0.07 0.29*** 0.05
0.34** 0.16 0.18 0.13
0.40*** 0.07 0.29*** 0.05
0.34** 0.16 0.18 0.13
0.03 0.06 0.05 0.05
0.03 0.06 0.05 0.05
0.03 0.06 0.09* 0.05




Estimated coefficients for the complete study population including significant vaccine preference actors (n = 610).a,b
Attribute levels Model1 Model 2
Coefficient Std. error Coefficient Std. error
Constanta Mean 1.35*** 0.28 4.18*** 1.06
SD 3.72* 0.26 4.07* 0.27
Clinical syndromes
Pertussis Mean 0.34** 0.16 0.35 0.51
SD 1.13 0.13 1.23 0.13
Herpes Zoster Mean 0.17** 0.15 0.02 0.47
SD 1.17 0.12 1.17 0.13
Pneumococcal disease Mean 0.52*** 0.13 0.40 0.40
SD 0.69 0.14 0.61 0.13
Influenza (ref) Mean 1.03 0.20 0.91 0.20
SD 1.76 1.64 1.81 1.72
Mortality
1% mortality (ref) Mean 0.56*** 0.11 0.37 0.11
SD 0.91* 0.09 0.87* 0.08
20% mortality Mean 0.56*** 0.10 0.37 0.29
SD 0.91* 0.09 0.87* 0.08
Susceptibility
1% susceptibility (ref) Mean 0.93 0.15 0.06 0.15
SD 0.80* 0.66 0.70 0.62
50% susceptibility Mean 0.14 0.11 0.36 0.33
SD 0.48 0.11 0.36 0.16
100% susceptibility Mean 0.79*** 0.11 0.30 0.36
SD 0.64 0.11 0.59 0.11
Vaccine effectiveness
50% vaccine effectiveness (ref) Mean 0.38*** 0.07 0.08 0.07
SD 0.29 0.09 0.18 0.16
100% vaccine effectiveness Mean 0.38*** 0.07 0.08 0.21
SD 0.29 0.09 0.18 0.16
Vaccine side-effects
Mild side-effects (ref) Mean 0.02 0.06 0.02 0.06
Severe side-effects Mean 0.02 0.06 0.02 0.20
Nr. of vaccinations
Vaccinating once (ref) Mean 0.03 0.06 0.39** 0.06
Vaccinating twice Mean 0.03 0.06 0.39** 0.20
Interactions
Health score * mortality 0.01*** 0.004
Health score * effectiveness 0.01* 0.003
Health score * nr. of vac. 0.004* 0.003
Prev.vac * pertussis 0.96*** 0.20
Prev.vac * herpes zoster 0.47** 0.19
Prev vac*pneumoccal disease 0.02 0.16
a Model 1 includes the interaction with received previous vaccinations. Only the significant interaction terms are shown.
b Model 2 includes the interaction with health score. Only the significant interaction terms are shown.
* P < 0.10.
** P < 0.05.
*** P < 0.01.
Table 5
The value and estimated vaccination rates for the influenza, pneumococcal disease, herpes zoster and pertussis vaccine.
Vaccinea Study population groups
50 years and older (n = 610) 50–65 years (n = 290) 65 years and older (n = 320)
Estimated vaccination rate (%) Estimated vaccination rate (%) Estimated vaccination rate (%)
Pneumococcal disease 68.1 58.1 76.2
Herpes Zoster 58.1 49.5 67.5
Pertussis 53.9 43.8 57.5
Influenza 54.3 42.2 65.5
a See Table 1 for the different vaccine/disease characteristics used to calculate the value.
2828 R. Eilers et al. / Vaccine 35 (2017) 2823–2830aged 65 year and older. Pertussis had the lowest estimated uptake
of 53.9% for older adults. Looking at the different age groups, for
persons aged 50–65, lowest estimate vaccination uptake was esti-
mated for influenza vaccination while for persons aged 65 years
and older, lowest vaccination uptake was estimated for pertussis
vaccination.4. Discussion
This experimental study examines the vaccine preferences and
vaccine acceptance among Dutch persons aged 50 years and older.
Respondents preferred protection against pneumococcal disease
over influenza and protection against influenza over pertussis
R. Eilers et al. / Vaccine 35 (2017) 2823–2830 2829and herpes zoster. Furthermore, high vaccine effectiveness, high
mortality and high susceptibility rates were also identified as pref-
erences. Susceptibility rate of an infectious disease seemed to be
the most important factor in the vaccination decision-making pro-
cess of older adults, followed by the clinical syndrome and mortal-
ity rate.
Our results suggest that older adults are most likely to accept
pneumococcal vaccination from the four available vaccines
(influenza, pertussis, herpes zoster and pneumococcal disease),
resulting in the highest estimated uptake of 68.1%. For all vaccines,
the estimated uptake was lower for persons aged 50–65 compared
to persons aged 65 year and older. While for persons aged 65 years
and older vaccination uptake for influenza was higher than for per-
tussis vaccination and similar to that for herpes zoster, little differ-
ence in uptake between influenza and pertussis was found for 50–
65 year olds with higher uptake for herpes zoster.
Our estimated influenza vaccination uptake of 65.6% among
persons aged 65 years and older is in line with the actual uptake
of 67% among this population in 2014 [24]. In this age group, also
the highest vaccine uptake of the study was estimated for pneumo-
coccal disease with 76.2%.
Although protection against the clinical symptoms of pneumo-
coccal disease seems to a preference by the total study population,
preference concerning the clinical symptoms seems to be age-
dependent. For persons aged 50–65 years, a vaccine that protects
against the clinical symptoms of pertussis is preferred over a vac-
cine that protects against the clinical symptoms of influenza. This
is the opposite for the 65 years and older population. In addition,
persons aged 50–65 years prefer a vaccine that protects against
the clinical symptoms of influenza over a vaccine that protects
against the clinical syndrome of herpes zoster, while the popula-
tion aged 65 years and over did not report significant preferences
for this vaccine compared to influenza vaccination.
Differences in vaccine preferences were also observed between
people that received earlier influenza vaccination or not as well as
between persons with higher or lower self-perceived health scores.
Older adults that perceive themselves as healthier, preferred pre-
vention against diseases with high mortality rates, high vaccine
effectiveness and vaccinating twice more compared to older adults
with lower health scores do. The preference to receive two vaccina-
tions might seem particular; however, it could be possible that
these people feel that they will be better protected with a second
vaccination.
Older adults that received the earlier influenza vaccination
reported a higher preference for vaccination against the clinical
syndromes of influenza compared to pertussis and herpes zoster
compared to persons that did not receive earlier influenza vaccina-
tion. This seems logical, as older adults that accept vaccination
against influenza probably perceive influenza as a serious disease
And given that influenza vaccination program is already in place
it might be that this vaccine will be preferred because of its
familiarity.
In general, the implementation of additional vaccines to achieve
the highest possible uptake is challenging. Processes such as
immunosenence (the gradual deterioration of the immune func-
tion) lead to a biological susceptibility of which people may not
be aware. With regard to vaccine effectiveness, immunosenescence
poses a challenge as well because it may lead to decreased vaccine
effectiveness. Vaccination response might be better when vaccina-
tion is offered before this process sets in. However, it has to be
acknowledged that the estimated vaccination rates for persons
aged 50–65 years were lower, therefore the pros and cons of intro-
ducing vaccination at earlier age should be weighed. Also, the pos-
sibility of waning immunity has to be kept in mind. Since
respondents prefer to be vaccinated if they perceived themselves
highly susceptible, it is important to inform the older adults ontheir biological susceptibility. Given the important role of the gen-
eral practitioner in the Netherlands as advisor and executioner of
the influenza vaccination, they probably are the most appropriate
source of information.
Vaccination may yield individual and societal benefits. Aspects
such as vaccine effectiveness, disease mortality rate and suscepti-
bility are important to focus on with the vaccine information pro-
vision. This may lead to achieving the highest possible uptake and
therefore contribute to healthy ageing. Currently, only influenza
vaccination is offered to persons aged 60 years and older (and to
certain risk groups) in the Netherlands. This vaccination is offered
free of charge. In the current study, vaccines were offered to the
respondents indicating no costs. It is not clear yet in what way
additional vaccines may be implemented at this point so this
should be taken into consideration. Still, for any vaccination pro-
gram to be successful, acceptation is crucial. This study therefore
gives insight in the potential success of the implementation of
new vaccines.
This study is, to our knowledge, the first DCE study conducted
about older adult vaccination. Our results are in line with recent
other studies that examine vaccine specific attributes in different
Western populations. Studies on children [25–27], parents [28–
32] and the general population [33] all show preferences for high
vaccine effectiveness. In most studies, respondents significantly
preferred minor side-effects or low chance on (severe) side-
effects over high levels of side-effects, while in our study, mild
side-effects did not affect vaccine decision-making [25,30–32,34].
It could be possible that side-effects following vaccination of chil-
dren is found to be more important than side-effects following vac-
cination of adults. Our study results are more similar to the
observations of Determann et al. and Hofman et al. who suggest
that side-effects compared to other vaccine characteristics are less
important when deciding on vaccinations [27,33]. In contrast to
the current study, sex and education in fluenced vaccine related
preferences in these studies.
4.1. Limitations
Using discrete choice experiments it was possible to indicate
the relative importance of the different attributes in the experi-
ments. In addition, we could calculate potential up-take/use of
the chosen measure so it can provide input for realistic implemen-
tation strategies. Another advantage is that a DCE is always com-
plementary to a regular questionnaire, this way covariates can be
included to explain differences in preferences.
However, our study has some limitations. First of all, this DCE
was conducted among older adults, while previous research shows
that DCEs pose a cognitive burden on participants [8], especially if
they are older [35]. To overcome this concern and to ensure that
older adults would be able to fill in the choice tasks, extensive pilot
testing was incorporated which included think out loud testing and
choice tasks were simplified as much as possible. We included, for
example, vaccine effectiveness as a two level attribute (100% ver-
sus 50%). We therefore assume that respondents were capable to
complete the DCE as provided to them. A limiting factor, related
to the simplification, may be that no attribute was included that
concerns the influence of the advice of a general practitioner. From
literature, it is known that the general practitioner plays an impor-
tant role in the vaccination decision-making of older adults. Fur-
ther research has to be conducted to identify the relative
importance of the general practitioner alongside the disease and
vaccine characteristics.
Although the selection of the respondents in our study was
carefully planned based on random sampling in specific each cate-
gory and the response rate was comparable with other DCE studies,
there might be selection bias in our study due to the higher num-
2830 R. Eilers et al. / Vaccine 35 (2017) 2823–2830ber of persons between the age of 60 and 70 years and higher edu-
cated people. Their opinions are therefore overrepresented in the
choice modelling while there is an underrepresentation of the vac-
cine preference for the persons aged 80 and older and lower edu-
cated persons. This might influence the results because previous
research suggests age dependent attitudes towards clinical symp-
toms and a more critical attitude towards vaccination in relation
to a higher educational level [10,36]. However, our estimated influ-
enza vaccination acceptance rate is in line with the actual influenza
vaccination acceptance rate, which ensures some validity of the
data.
4.2. Conclusion
The prominent factors that influence the vaccination choices of
older adults are the vaccine effectiveness, the susceptibility for an
infectious disease and the mortality caused by an infectious dis-
ease. Pneumococcal vaccination could be the most suitable candi-
date for implementation since this vaccine has the highest
potential vaccine uptake. Moreover, vaccine preferences were
associated with age, having received earlier influenza vaccination
and the self-perceived health score. These findings need to be
taken into account when considering implementation of vaccina-
tion in older adults. Therefore, information provision accompanied
with the implementation of a new vaccine has to be tailored for the
individual and the vaccine it concerns.
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